The Generation of Six Clinical-Grade Human Embryonic Stem Cell Lines  by Crook, Jeremy Micah et al.
Cell Stem Cell
CorrespondenceThe Generation of Six Clinical-Grade
Human Embryonic Stem Cell Lines
Jeremy Micah Crook,1,3,* Teija Tuulikki Peura,2 Lucy Kravets,1 Alexis Gina Bosman,2 Jeremy James Buzzard,1
Rachel Horne,1 Hannes Hentze,1 Norris Ray Dunn,1,3 Robert Zweigerdt,1,3 Florence Chua,1 Alan Upshall,1
and Alan Colman1,3
1ES Cell International Pte Ltd., Singapore 138667
2Sydney IVF, Sydney, NSW 2000, Australia
3Present address: Institute of Medical Biology, Singapore Stem Cell Consortium, Singapore 138648.
*Correspondence: jeremy.crook@imb.a-star.edu.sg
DOI 10.1016/j.stem.2007.10.004Theedict forproducingclinically compli-
ant humanembryonic stemcells (hESCs)
necessitates adherence to global ethi-
cal standards for egg procurement
and embryo donation, conformity to
regulations controlling clinical-grade
cell and tissue product development,
and compliance with current good
tissue and manufacturing practices490 Cell Stem Cell 1, November 2007 ª2(cGTPs and cGMPs, respectively).
For example, the U.S. FDA Center for
Biologics Evaluation and Research
recently promulgated regulations re-
garding human cells and cellular-
based products (HCT/Ps) intended for
tissue repair or replacement. Issued
under Code of Federal Regulations
parts 1270 and 1271 (Code of Federal007 Elsevier Inc.Regulations, 2006a, 2006b), the rules
are broadened by requirements for
donor selection andcGMPs forHCT/Ps.
By adhering to regulations and in antic-
ipation of future standards, we have
generated six clinical-grade hESC
lines. Here we describe their manu-
facture, from embryo procurement to
line characterization, including sterilityFigure 1. Overview of Activities and Requirements for cGMP hESC Line Derivation, Banking, and Characterization
The project commenced with the procurement of suitable embryos, paralleled by the selection, optimization, and verification of protocols inclusive of
cGMP-compliant reagents and materials for hESC derivation, culture, cryopreservation, storage, and biosafety testing. Once validated, all protocols
were translated to batch record and/or standard operating procedure (SOP) format for cGMP application. Qualified personnel received instruction for
protocol execution according to principles of cGMP. On-site audits of selected key organizations/facilities for cGMP compliance were performed.
Appropriate documentation confirming cGMP compliance was attained for all other supporting services (e.g., reagent production). cGMP activities
were subsequently undertaken within an Australian Therapeutic Goods Administration (TGA) accredited cGMP facility (Q-GEN Pty Ltd) for fibroblast
feeder banking followed by hESC line derivation, expansion, and cryopreservation for MCB production. All MCBs were transferred to an accredited
facility for cGMP cryogenic storage. After characterization of each line, including biosafety testing, all documentation (exceeding 1000 pages per
hESC line) was collated for final review and confirmation of successful cGMP line and bank production.
Cell Stem Cell
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knowledge, the lines represent the first
to have been produced in compliance
with international regulatory require-
ments, suitable for therapeutic use.
Commencement of the project was
contingent on the ethical procurement
of quality embryos. Principles dictate
that donors of blastocysts act volun-
tarily without coercion and are con-
versant of procedure and the option
of ‘‘informed refusal’’ (Committee on
Guidelines for Human Embryonic
Stem Cell Research, National Re-
search Council, 2005; International
Society of Stem Cell Research, 2006;
Code of Federal Regulations, 2006a,
2006b). Accordingly, we applied a
comprehensive informed consent pro-
cess (Table S1 in the Supplemental
Data available with this article online),
regulated by the Australian Common-
wealth Research Involving Human
Embryos Act 2002. Supernumerary
embryos were procured after autono-
mous consent by suitable informed
donors and with the approval of an
Institutional Review Board (IRB) and
the Australian National Health and
Medical Research Council (NH&MRC)
Embryo Research Licensing Com-
mittee. Approved donors satisfied
requirements for lifestyle and blood
testing (Table S2). Based on donor
screening, 43 embryos frozen at
blastocyst stage and stored for a mini-
mum of 4 years were identified for
the project.
The rigorous standards for obtaining
embryos were matched by meticu-
lously adhering to optimized protocols
for embryo handling and tissue culture
to maximize success within the con-
straints of cGMP. This assured the
efficiency of hESC line derivation was
similar to or higher than earlier reports
of conventional research-grade line
production (Cowan et al., 2004; Mitali-
pova et al., 2003; Klimanskaya et al.,
2005; Stephenson et al., 2006). Thirty-
six embryos were plated after thawing,
with eight developing to putative hESC
lines (22%; Table S3).
The ‘‘gold-standard’’ hESC line
would be derived, cultured, and
banked under defined conditions, inde-
pendent of feeder cells and animal
biologics. Although there have been
many attempts to achieve this goal,including the development of xeno-
freeplatforms, their utility is contentious
(Rajala et al., 2007). Potential limitations
relate to the cost of implementation,
efficacy for hESC derivation and ex-
pansion, and impact on hESC differen-
tiation and stability during prolonged
culture. Accordingly, the application of
current putative fully defined xeno-free
methods for translational application
and clinical product development is
uncertain. Xeno-free methods are also
unnecessary because the use of suit-
ably qualified nonhuman animal-de-
rived products such as bovine-sourced
serum or albumin in hESC culture me-
dium guarantees a robust and quality
product and is acceptable from a regu-
latory perspective (Rajala et al., 2007;
Fink, 2004). In support, the U.S. FDA
has approved the therapeutic use of
at least three live-cell products (Apli-
graf, Dermograft, and OrCel) where
fetal bovine serum (FBS) and other
bovine materials have been used in
manufacture. Moreover, previous con-
cerns about a potentially immunogenic
nonhuman sialic acid, Neu5Gc, arising
on the surface of hESCs grown in the
presence of animal-derived compo-
nents (Martin et al., 2005) are allayed
by a recent finding that this is reversible
by subsequent growth under animal
component-free conditions (Heiskanen
et al., 2007). Whether animal derived
or synthetic, all reagents must be
screened for unwanted adventitious
agents such as microbial, viral, exoge-
nous pyrogen, or chemical contami-
nants.
Given the limited availability of
quality supernumary embryos and the
cost burden of cGMP, we employed
embryo and cell culture platforms that
would guarantee production of bona
fide hESC lines that are clinically
compliant. Thus, all lines were gene-
rated from embryos initially plated
and cultured in human serum albumin
(HSA)-based blastocyst thaw and
culture media, respectively (Table S4).
Once isolated, hESCs were main-
tained on FDA-approved clinical-
grade human foreskin fibroblasts in
cGMP-manufactured bovine serum
albumin (BSA)-based serum-replace-
ment (SR) containing medium (Table
S4). Prior to use, fibroblast feeders
were derived and maintained inCell Stem Cell 1,customized cGMP-grade FBS-based
medium. Antibiotics were omitted
from all media to avoidmasking poten-
tial low-level bacterial contamination
during culture. Their exclusion also
forestalls regulatory concerns for clini-
cal safety due to risk of hypersensitivity
reactions in patients (Guidance for
Human Somatic Therapy and Gene
Therapy, 1998). Significantly, all hESC
lines were produced under conditions
free of live xeno-biologics, which qual-
ifies them as nonxenogeneic for cell
transplantation purposes (Code of
Federal Regulations, 2006a, 2006b).
Embryos were hatched from the
zona pellucida and replated whole (17
embryos) or bisected (19 embryos)
for isolation and replating of the inner
cell mass (ICM) alone. Excision of the
ICM was performed manually with
a splitting blade, avoiding the potential
regulatory hurdles associated with im-
munosurgery as well as costly devel-
opment of cGMP-grade antibodies
and complement (Peura et al., 2007;
Ellerstrom et al., 2006). ICM out-
growths formed 1–2 days after replat-
ing, with putative hESC lines being
visible 10–20 days thereafter. Similar
to ICM excision, hESC outgrowths
were isolated manually from the ICM
and cultured on fibroblasts in the ab-
sence of gelatin substrate. Of the lines
that were successfully derived, four
were from bisected embryos (21%;
ESI-013, ESI-014, ESI-017, and ESI-
051) and four were not (25%; ESI-
027, ESI-035, ESI-049, and ESI-053).
Hence the efficiency of derivation
was similar for whole and bisected
embryos. Applying the grading system
stipulated by Stephenson et al. (2006),
embryos were evaluated for expansion
status, ICM appearance, and trophec-
toderm appearance (Table S3).
After manual dissection for the first
two to three passages, bulk passaging
or final harvesting of cultures was
performed by enzymatic dissociation
using cGMP-grade collagenase. This
method resulted in the replating or
harvest of hESC aggregates, with
less than 10% fibroblast contamina-
tion for ongoing subculture or master
cell bank (MCB) production. Our as-
sessment of fibroblast contamination
was based on flow cytometry analysis
of fibroblasts within ESI-017 culturesNovember 2007 ª2007 Elsevier Inc. 491
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after Derivation, Culture through Eight Passages, Cryopreservation, Thawing, and Reculture through More Than Five Passages492 Cell Stem Cell 1, November 2007 ª2007 Elsevier Inc.
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subculture allays concerns for putative
karyotype changes associated with
single-cell subculture (Buzzard et al.,
2004; Mitalipova et al., 2005).
MCBs were successfully preserved
after seven to nine passages by control
rate freezing incorporating a cGMP-
manufactured nonxeno and protein-
free medium and hermetically sealed
straws. MCBs comprised between 40
and 60 straws, with 3 3 106 cells per
straw. All straws of an individual MCB
were prepared from the same single
pool/batch of hESCs. All banks were
confirmed microbe free, including
mycoplasma (Table S5).
Immediately after banking, hESC
lines were karyotyped prior to further
characterization (Table S3). Of the
eight lines derived, six are karyotypi-
cally normal (ESI-014, ESI-017, ESI-
035, ESI-049, ESI-051, and ESI-053)
and two are trisomic mosaic for chro-
mosome 16 (ESI-013 and ESI-027).
The normal lines (Figure 2A and Table
S3) comprise hESCs that can be
banked, thawed, and recovered for
prolonged subculture. Cells show
normal growth kinetics (Table S3),
express markers for undifferentiated
status (Figures 2B–2D, Figures S1A
and S1B, and Table S3), and form
colonies exhibiting undifferentiated
gross morphology (Figure 2B).
DNA fingerprinting of genetically
aberrant lines confirmed the presence
of triallelic profiles indicative of meiotic
errors of parental origin. Hence the
original embryos were trisomic ratherthan trisomy arising during or after
hESC line derivation and culture. Fluo-
rescent in situ hybridization indicated
trisomy in 53% of ESI-013 cells,
whereas ESI-027 exhibited trisomy in
63% of cells. Nontrisomic cells were
diploid. Trisomy 16 is estimated to
occur inmore than 1% of clinically rec-
ognized pregnancies, making it the
most commonly occurring trisomy in
humans (Benn, 1998). Nonmosaic tri-
somy 16 is prevalent in males and is
associated with a high probability
of fetal death, preterm delivery, and
intrauterine growth retardation. Con-
versely, trisomy 16 mosaicism is ele-
vated in female karyotypes, exhibits
a less severe nonlethal phenotype,
and is often difficult to prove by stan-
dard chromosomal analysis. Although
both mosaic lines showed normal
growth behavior during cGMP deriva-
tion and expansion for banking, for
the present each has been excluded
from further characterization and con-
sideration for clinical use.
Consistent with being undiffer-
entiated, all the diploid, character-
ized lines are pluripotent. hESCs
formed teratomas in SCID mice com-
prising endoderm, ectoderm, and
mesoderm derivatives (Figure 2E and
Figure S1C). RT-PCR of hESC-derived
embryoid bodies (EBs) identified
mRNA for IGF-2 and Hand-1 (meso-
dermal markers), Tubb-3 and Nestin
(ectodermal markers), and H19 and
Cerberus-1 (endodermal markers)
(Figure 2F and Figure S1D). In addition,
each line has been induced to cardio-Cell Stem Cell 1,myogenic and pancreatic progenitor
cells by in vitro methods for directed
hESC differentiation (Table S3). For
cardiomyocyte induction, floating EBs
display robust cardiogenic contraction
after 9–21 days in END2 cell-condi-
tioned serum-free medium (Graichen
et al., 2007; Dai et al., 2007). Specific
immunolabeling of cardiac proteins
Nkx2.5,myosin light chain 2a (MLC2a),
cardiac a-myosin heavy chain (a-MHC),
and the sarcomere marker a-actinin
confirms the formation of extensive
cardiomyocyte clusters within EBs
and among seeded cells derived from
EBs (Figure 2G). Cross-striations char-
acteristic of sarcomeric structures
were observed after a-actinin and
MLC2a labeling (Figure 2G). Differenti-
ation to pancreatic progenitors was
supported by Pdx-1 induction (D’Ales-
sandro et al., 2007; Phillips et al.,
2007). Pdx-1 expression identifies
early pancreatic progenitors in the
vertebrate embryo, and its activation
in vitro is considered a prerequisite
for pancreatic differentiation and ulti-
mately the formation of endocrine cell
types fromdifferentiating hESCs (Ashi-
zawa et al., 2004). Pdx-1 expression
was first detected around day 12 of
culture (data not shown) and persisted
to day 34 (Figure 2H). Whole-mount
immunohistochemistry revealed Pdx-
1-positive cells to be confined to dis-
crete domains within individual EBs,
often forming clusters of ribbons
(Figure 2H).
Having confirmed the stemness of
each line, four of the six hESC banks(A) A Giemsa band karyogram showing normal female karyotype.
(B) Bright-field (scale bar, 1 mm) and fluorescent (scale bar, 400 mm) microscopic images showing undifferentiated (non-cystic) colony morphology
and qualitative immunocytochemistry of cells positive for transcription factors Oct-4, Nanog, and Sox-2 and extracellular matrix markers Tra 1-60 and
Tra 1-81. Insets represent DAPI staining.
(C) RT-PCR showing transcript expression of marker genes Oct-4, Nanog, TDGF-1, UTF-1, and Sox-2. Lane 1, 100 bp DNA ladder.
(D) Quantitative flow cytometry indicating robust expression of Oct-4, alkaline phosphatase (Tra 2-54), Tra 1-60, Tra 1-81, and surface-antigen
SSEA-4.
(E) Histology of teratomas. Left, large (scale bar, 400 mm) and small (scale bars, 50 mm) panels illustrating H&E staining. Teratomas comprised
ectoderm (neuroepithelium), endoderm (gut-like epithelium), and mesoderm (cartilage). Right, immunolabeling of ectoderm (a-GFAP), endoderm
(a-Keratin Endo-A), mesoderm (a-Desmin), and proliferating cells (a-Ki67).
(F) RT-PCR of in vitro-derived EBs showing transcript for IGF-2 andHand-1 (mesodermal markers), Tubb-3 andNestin (ectodermal markers), andH19
and Cerberus-1 (endodermal markers). Lane 1, 100 bp DNA ladder.
(G) Cardiomyocyte induction. Contracting foci indicative of cardiomyocytes were typically observed proximal to or within cystic areas of an EB. Scale
bar, 500 mm. Immunoreactivity (red labeling) to a-actinin and a-MHC on serial EB sections and MLC2a on seeded cells indicated the formation of
cardiomyocyte clusters. Immunoreactivity to Nkx2.5 localized in the nucleus indicated that most if not all a-MHC- and MLC2a-positive cardiomyo-
cytes costained with this cardiomyocyte-specific transcription factor. Note cross-striations typical of sarcomere structures in the middle-left and
lower-right panels. Hoechst staining of cell nuclei is shown in blue. Scale bars, 50 mm. Cell nuclei in seeded cells appeared larger than EB-embedded
cells at the same magnification.
(H) Expression of Pdx-1was determined by Q-PCR. On day 35, Pdx-1 levels of ESI-035 and NIH-registered reference line hES-3 are equivalent. Pdx-
1-positive b-like cells (red labeling) reside within discrete regions in individual day 34 ESI-035 EBs. Inset represents DAPI staining. Error bars represent
standard error of the mean.November 2007 ª2007 Elsevier Inc. 493
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tested free of a variety of human and
nonhuman pathogens by standard
methods for mammalian cell bank
and tissue screening (Table S5). The
remaining two banks will be similarly
screened.
In summary, the hESC lines de-
scribed were manufactured according
to cGTP and cGMP for clinical com-
pliance and therapeutic application.
We have developed and applied
a model process comprising stan-
dardized protocols with validated re-
agents, materials, and procedures
verified by documentation for regula-
tory approval. All lines remain patho-
gen free, karyotypically stable, and
undifferentiated after derivation, ex-
pansion, cryopreservation for bank-
ing, thawing, and prolonged sub-
culture. Surface antigens and gene
expression signatures of undiffer-
entiated hESCs correlate with in vitro
EB and in vivo teratoma formation as
consummate measures of develop-
mental potency for hESCs. Directed
differentiation to cardiomyogenic and
pancreatic progenitor cells confirms
the capacity for each line to be con-
verted to specialized somatic cell
types. As a source of clinical-grade
stem cells, we anticipate the cell
banks will facilitate the translation of
hESC research and development to
cell-based therapies. In addition, as
fully characterized cell lines, they are
attractive candidates for drug screen-
ing relevant to pharmacotherapeutics.
The lines will be available for research
at low cost and with no intellectual
property reach-through claims from
the A*Star (http://www.a-star.edu.sg)
Singapore Stem Cell Consortium
Bank. ESI-017, ESI-035, ESI-049, and
ESI-053 are immediately available,
and ESI-014 and ESI-051 will be
available after completion of biosafety
testing. Clinical grade stocks will be494 Cell Stem Cell 1, November 2007 ª2accessible under licensed agreement
with ES Cell International Pte Ltd
(http://www.escellinternational.com).
Supplemental Data
Supplemental Data include Supplemental Ex-
perimental Procedures, one figure, and seven
tables and can be found with this article online
at http://www.cellstemcell.com/cgi/content/
full/1/5/490/DC1/.
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